Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer's disease-Reference-Cited by-同舟云学术

Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer's disease

Published:2017-04 Issue: Volume:116 Page:82-97
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Caioli Silvia,Severini Cinzia,Ciotti Teresa,Florenzano Fulvio,Pimpinella Domenico,Petrocchi Passeri Pamela,Balboni Gianfranco,Polisca Patrizio,Lattanzi Roberta,Nisticò Robert,Negri Lucia,Zona Cristina

Funder

Fondazione Sovena, Rome, Italy

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference90 articles.

1. Cell mediators of inflammation in the Alzheimer disease brain;Akiyama;Alzheimer Dis. Assoc. Disord.,2000

2. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors;Alberdi;Cell Calcium,2010

3. Triazine compounds as antagonists at Bv8-prokineticin receptors;Balboni;J. Med. Chem.,2008

4. Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase;Banke;J. Neurosci.,2000

5. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis;Baron;Muscle Nerve,2005

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Prokineticins on Cerebral Cell Function and Blood–Brain Barrier Permeability;International Journal of Molecular Sciences;2023-10-21

2. Therapeutic Potential of Targeting Prokineticin Receptors in Diseases;Pharmacological Reviews;2023-09-08

3. Blocking prokineticin receptors attenuates synovitis and joint destruction in collagen-induced arthritis;Journal of Molecular Medicine;2023-03-29

4. Non-Peptide Agonists and Antagonists of the Prokineticin Receptors;Current Issues in Molecular Biology;2022-12-12

5. Potential Clinical Role of Prokineticin 2 (PK2) in Neurodegenerative Diseases;Current Neuropharmacology;2022-11